Yanqiu Zhao
A5049277287- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Brain Metastases and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- MicroRNA in disease regulation
- Pancreatic and Hepatic Oncology Research
- Nanoparticle-Based Drug Delivery
- Monoclonal and Polyclonal Antibodies Research
- Genetic factors in colorectal cancer
- Thyroid Cancer Diagnosis and Treatment
- RNA modifications and cancer
- Cancer Research and Treatments
- HIV/AIDS Research and Interventions
- Hepatocellular Carcinoma Treatment and Prognosis
- Hedgehog Signaling Pathway Studies
Henan Cancer Hospital
2016-2025
Zhengzhou University
2016-2025
Kunming Medical University
2024-2025
Peking University
2024-2025
First Affiliated Hospital of Harbin Medical University
2024-2025
Cancer Hospital of Huanxing Chaoyang District Beijing
2025
Harbin Medical University
2025
Sichuan International Studies University
2022-2024
Ludong University
2024
Peking University Cancer Hospital
2024
IntroductionSintilimab, an anti–programmed death 1 antibody, plus pemetrexed and platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We conducted randomized, double-blind, 3 study to compare the safety of sintilimab with placebo, both combination such chemotherapy (ClinicalTrials.gov: NCT03607539).MethodsA total 397 patients previously untreated, locally advanced or metastatic without sensitizing EGFR anaplastic lymphoma kinase genomic aberration were...
Importance Programmed cell death ligand 1 inhibitors combined with chemotherapy has changed the approach to first-line treatment in patients extensive-stage small lung cancer (SCLC). It remained unknown whether adding a programmed (PD-1) inhibitor provided similar or better benefits SCLC, which would add evidence on efficacy of checkpoint SCLC. Objective To evaluate and adverse event profile PD-1 serplulimab plus compared placebo as Design, Setting, Participants This international,...
Inhibiting vascular endothelial growth factor (VEGF) function can improve the efficacy of immunotherapy by modulating tumor immune microenvironment. AK112 is first-in-class humanized IgG1 bispecific antibody targeting programmed death-1 (PD-1) and VEGF. This study aimed to evaluate safety combined with chemotherapy in patients advanced non-small cell lung cancer (NSCLC).This open-label, multicenter, phase II clinical trial was conducted 11 hospitals China. Eligible participants were adults...
Osimertinib has shown promising activity in patients with leptomeningeal metastases (LMs) of EGFR-positive NSCLC at 160 mg once daily (qd) (BLOOM; NCT02228369). We report LM osimertinib (80 qd) a retrospective analysis studies across the AURA program (AURA extension, AURA2, AURA17, and AURA3).Patients EGFR T790M-positive advanced progression after previous EGFR-tyrosine kinase inhibitor therapy received qd). Patients central nervous system (CNS) (including LMs) were eligible if lesions...
Abstract Exosomes are small endogenous membrane vesicles that can mediate cell communication by transferring genetic materials. Based on that, exosomes have always been discussed as a cargo carrier for microRNA (miRNA) transportation. Accumulating data reported the inhibitory effects of microRNA-193a (miR-193a) non-small lung cancer (NSCLC) progression. However, mechanisms miR-193a delivery to cells and in not explored clearly NSCLC. Given this work aims decode exosomal cisplatin (DDP)...
This multicenter phase-II trial aimed to investigate the efficacy, safety, and predictive biomarkers of toripalimab plus chemotherapy as second-line treatment in patients with EGFR-mutant-advanced NSCLC. Patients who failed from first-line EGFR-TKIs did not harbor T790M mutation were enrolled. Toripalimab carboplatin pemetrexed administrated every three weeks for up six cycles, followed by maintenance pemetrexed. The primary endpoint was objective-response rate (ORR). Integrated biomarker...
Epidermal growth factor receptor exon 20 insertion mutations (EGFRexon20ins) are detected in approximately 2% of patients with non-small cell lung cancer (NSCLC). Due to a lack effective therapy, the prognosis these is typically poor. Sunvozertinib (DZD9008) was designed as an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor, showing activity against EGFRexon20ins other mutations. In both lines xenograft models, sunvozertinib shows potent antitumor activity. two...
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been widely used for human non-small-cell lung cancer (NSCLC) treatment. However, acquired resistance to EGFR-TKIs is the major barrier of treatment success, and new mechanism remains be elucidated. In this study, we found that elevated NADPH oxidase 4 (NOX4) expression was associated with resistance. Gefitinib first-generation FDA-approved EGFR-TKI, osimertinib third-generation EGFR-TKI. We demonstrated NOX4...
This open-label, phase 3 trial (ALTA-3; NCT03596866) compared efficacy and safety of brigatinib versus alectinib for ALK+ NSCLC after disease progression on crizotinib.Patients with advanced that progressed crizotinib were randomized 1:1 to 180 mg once daily (7-d lead-in, 90 mg) or 600 twice daily, aiming test superiority. The primary end point was blinded independent review committee-assessed progression-free survival (PFS). Interim analysis futility planned at approximately 70% 164...
We conducted a proof-of-concept, phase 2 trial to assess neoadjuvant SHR-1701 with or without chemotherapy, followed by surgery radiotherapy, and then consolidation in unresectable stage III non-small-cell lung cancer (NSCLC). In the primary cohort of patients receiving combination therapy (n = 97), both endpoints were met, post-induction objective response rate 58% (95% confidence interval [CI] 47–68) an 18-month event-free survival (EFS) 56.6% CI 45.2–66.5). Overall, 27 (25%) underwent...
Abstract Background Treatment options for Chinese patients with locally advanced or metastatic squamous‐cell non‐small‐cell lung cancer (sqNSCLC) after failure of first‐line chemotherapy are limited. This study (ORIENT‐3) aimed to evaluate the efficacy and safety sintilimab versus docetaxel as second‐line treatment in sqNSCLC. Methods ORIENT‐3 was an open‐label, multicenter, randomized controlled phase 3 trial that recruited stage IIIB/IIIC/IV sqNSCLC platinum‐based chemotherapy. Patients...
9002 Background: Sunvozertinib(DZD9008) is a rationally designed selective, irreversible EGFR exon20 insertion (exon20ins) inhibitor with wild-type selectivity. Here we reported the results of WU-KONG6, first pivotal study sunvozertinib in previously treated NSCLC patients exon20ins. Methods: WU-KONG6 (NCT05712902 and CTR20211009) phase II, multi-center exon20ins, whose diseases had progressed on or were after platinum-based chemotherapy. Tumor tissue exon20ins status was tested by local...
468214 Background: KRAS G12C mutation occurs in approximately 4% of non-small cell lung cancers (NSCLC) China. Glecirasib (Jacobio, Beijing, PRC) is a potent and highly selective covalent oral inhibitor G12C. Methods: This phase 2 single-arm study (NCT05009329) glecirasib was conducted China at 43 sites, enrolling participants with locally advanced or metastatic mutated NSCLC. Subjects must have received prior platinum-based therapy an immune checkpoint (ICI) as well appropriate targeted...